Serotonin, schizophrenia and antipsychotic drug action

Research output: Contribution to journalArticle

175 Citations (Scopus)

Abstract

A rapidly growing body of data suggests that dysfunction in serotonergic (5-HT) function may be involved in the pathophysiology of schizophrenia, and that pharmacologic agents for this illness have their therapeutic effects mediated through serotonergic mechanisms. The purpose of this paper is to critically review data relevant to 5-HT's role in the pathophysiology and drug treatment of schizophrenia. Pathophysiologic evidence includes the psychotomimetic effects of lysergic acid (LSD), postmortem studies, single-dose `challenge' studies and investigations of CSF and peripheral levels of 5-HT and its metabolites. The current nomenclature, potential therapeutic effects and importance of 5-HT receptor subtype antagonism will be examined. In addition, relatively novel strategies of 5-HT uptake blockade and direct acting 5-HT agonists will be assessed. A hypothesis of cortical-subcortical imbalance with an increase in subcortical 5-HT function responsible for positive symptoms and a decrease in prefrontal 5-HT function responsible for negative symptoms is proposed. Future implications of these data are discussed.

Original languageEnglish (US)
Pages (from-to)187-202
Number of pages16
JournalSchizophrenia Research
Volume14
Issue number3
DOIs
StatePublished - 1995
Externally publishedYes

Fingerprint

Serotonin Agents
Antipsychotic Agents
Serotonin
Schizophrenia
Therapeutic Uses
Lysergic Acid
Serotonin Receptor Agonists
Serotonin Receptors
Terminology
Pharmaceutical Preparations

Keywords

  • (Schizophrenia)
  • Antipsychotic drug
  • Serotonin
  • Serotonin receptor
  • Uptake blockade

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry
  • Behavioral Neuroscience
  • Neurology
  • Psychology(all)

Cite this

Serotonin, schizophrenia and antipsychotic drug action. / Breier, Alan.

In: Schizophrenia Research, Vol. 14, No. 3, 1995, p. 187-202.

Research output: Contribution to journalArticle

@article{6eef04b369b34b4a9ce23b7a17ac1b2c,
title = "Serotonin, schizophrenia and antipsychotic drug action",
abstract = "A rapidly growing body of data suggests that dysfunction in serotonergic (5-HT) function may be involved in the pathophysiology of schizophrenia, and that pharmacologic agents for this illness have their therapeutic effects mediated through serotonergic mechanisms. The purpose of this paper is to critically review data relevant to 5-HT's role in the pathophysiology and drug treatment of schizophrenia. Pathophysiologic evidence includes the psychotomimetic effects of lysergic acid (LSD), postmortem studies, single-dose `challenge' studies and investigations of CSF and peripheral levels of 5-HT and its metabolites. The current nomenclature, potential therapeutic effects and importance of 5-HT receptor subtype antagonism will be examined. In addition, relatively novel strategies of 5-HT uptake blockade and direct acting 5-HT agonists will be assessed. A hypothesis of cortical-subcortical imbalance with an increase in subcortical 5-HT function responsible for positive symptoms and a decrease in prefrontal 5-HT function responsible for negative symptoms is proposed. Future implications of these data are discussed.",
keywords = "(Schizophrenia), Antipsychotic drug, Serotonin, Serotonin receptor, Uptake blockade",
author = "Alan Breier",
year = "1995",
doi = "10.1016/0920-9964(94)00043-8",
language = "English (US)",
volume = "14",
pages = "187--202",
journal = "Schizophrenia Research",
issn = "0920-9964",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Serotonin, schizophrenia and antipsychotic drug action

AU - Breier, Alan

PY - 1995

Y1 - 1995

N2 - A rapidly growing body of data suggests that dysfunction in serotonergic (5-HT) function may be involved in the pathophysiology of schizophrenia, and that pharmacologic agents for this illness have their therapeutic effects mediated through serotonergic mechanisms. The purpose of this paper is to critically review data relevant to 5-HT's role in the pathophysiology and drug treatment of schizophrenia. Pathophysiologic evidence includes the psychotomimetic effects of lysergic acid (LSD), postmortem studies, single-dose `challenge' studies and investigations of CSF and peripheral levels of 5-HT and its metabolites. The current nomenclature, potential therapeutic effects and importance of 5-HT receptor subtype antagonism will be examined. In addition, relatively novel strategies of 5-HT uptake blockade and direct acting 5-HT agonists will be assessed. A hypothesis of cortical-subcortical imbalance with an increase in subcortical 5-HT function responsible for positive symptoms and a decrease in prefrontal 5-HT function responsible for negative symptoms is proposed. Future implications of these data are discussed.

AB - A rapidly growing body of data suggests that dysfunction in serotonergic (5-HT) function may be involved in the pathophysiology of schizophrenia, and that pharmacologic agents for this illness have their therapeutic effects mediated through serotonergic mechanisms. The purpose of this paper is to critically review data relevant to 5-HT's role in the pathophysiology and drug treatment of schizophrenia. Pathophysiologic evidence includes the psychotomimetic effects of lysergic acid (LSD), postmortem studies, single-dose `challenge' studies and investigations of CSF and peripheral levels of 5-HT and its metabolites. The current nomenclature, potential therapeutic effects and importance of 5-HT receptor subtype antagonism will be examined. In addition, relatively novel strategies of 5-HT uptake blockade and direct acting 5-HT agonists will be assessed. A hypothesis of cortical-subcortical imbalance with an increase in subcortical 5-HT function responsible for positive symptoms and a decrease in prefrontal 5-HT function responsible for negative symptoms is proposed. Future implications of these data are discussed.

KW - (Schizophrenia)

KW - Antipsychotic drug

KW - Serotonin

KW - Serotonin receptor

KW - Uptake blockade

UR - http://www.scopus.com/inward/record.url?scp=0028855452&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028855452&partnerID=8YFLogxK

U2 - 10.1016/0920-9964(94)00043-8

DO - 10.1016/0920-9964(94)00043-8

M3 - Article

C2 - 7539288

AN - SCOPUS:0028855452

VL - 14

SP - 187

EP - 202

JO - Schizophrenia Research

JF - Schizophrenia Research

SN - 0920-9964

IS - 3

ER -